HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

DA-125, a new antitumor agent, inhibits topoisomerase II as topoisomerase poison and DNA intercalator simultaneously.

Abstract
DA-125, a novel derivative of adriamycin, is known for its anti-cancer activity. In this study, the inhibitory mechanism of DA-125 on topoisomerase was investigated in the simian virus 40 (SV40) replicating CV-1 cell by studying the SV40 DNA replication intermediates and DNA-topoisomerase complexes. DNA-protein complexes that were formed in the drug-treated cells were quantitated by using a glass filter assay. SV40 DNA replication intermediates that were accumulated in the drug-treated CV-1 cell were analyzed in a high resolution gel. DA-125 did not accumulate B-dimers of SV40 DNA replication intermediates which were found in the adriamycin-treated CV-1 cells. DA-125 induced a dose-dependent formation of the DNA-protein complexes, while adriamycin did not. When adriamycin and etoposide (VP16) were added to the SV40-infected cells at the same time, adriamycin blocked the formation of the DNA-protein complexes induced by VP16 in a dose-dependent manner. However, DA-125 blocked the formation of the DNA-protein complexes induced by VP16 up to the maximum level of the DNA-protein complexes that were induced by DA-125 alone. Adriamycin and DA-125 did not inhibit the formation of the DNA-protein complexes that were caused by camptothecin, a known topoisomerase I poison. DA-125 is bifunctional in inhibiting topoisomerase II because it simultaneously has the properties of the topoisomerase II poison and the DNA intercalator. As a topoisomerase II poison, DA-125 alone induced dose-dependent formation of the DNA-protein complexes. However, as a DNA intercalator, it quantitatively inhibited the formation of the DNA-protein complexes induced by a strong topoisomerase II poison VP16. Furthermore considering that the levels of the DNA-protein complex induced by VP16 were decreased by DA-125 in terms of the topoisomerase II poison, we suggest that DA-125 has a higher affinity to the drug-binding sites of DNA than VP16 has.
AuthorsJinwook Seo, Hak Sung Lee, Minjun Lee, Mira Kim, Cha-Gyun Shin
JournalArchives of pharmacal research (Arch Pharm Res) Vol. 27 Issue 1 Pg. 77-82 (Jan 2004) ISSN: 0253-6269 [Print] Korea (South)
PMID14969343 (Publication Type: Comparative Study, Journal Article)
Chemical References
  • Antineoplastic Agents
  • Intercalating Agents
  • Proteins
  • Topoisomerase II Inhibitors
  • 7-O-(2,6-Dideoxy-2-fluoro-alpha-talopyranosyl)adriamycinone- 14-beta-alaniate hydrochloride
  • Etoposide
  • Doxorubicin
  • DNA
  • DNA Topoisomerases, Type II
  • Camptothecin
Topics
  • Animals
  • Antineoplastic Agents (pharmacology)
  • Camptothecin (pharmacology)
  • Chlorocebus aethiops
  • DNA (chemistry, drug effects)
  • DNA Replication (drug effects, physiology)
  • DNA Topoisomerases, Type II (biosynthesis, pharmacology)
  • Dimerization
  • Dose-Response Relationship, Drug
  • Doxorubicin (analogs & derivatives, pharmacology)
  • Etoposide (antagonists & inhibitors, pharmacology)
  • Haplorhini
  • Intercalating Agents (pharmacology)
  • Methods
  • Protein Biosynthesis
  • Proteins (chemistry)
  • Simian virus 40 (drug effects, growth & development)
  • Topoisomerase II Inhibitors
  • Vero Cells

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: